Skip to main content
Top
Published in: Pituitary 2/2017

01-04-2017

Apparent diffusion coefficient and pituitary macroadenomas: pre-operative assessment of tumor atypia

Authors: Benita Tamrazi, Melike Pekmezci, Mariam Aboian, Tarik Tihan, Christine M. Glastonbury

Published in: Pituitary | Issue 2/2017

Login to get access

Abstract

Rationale and objectives

Pituitary macroadenomas are predominantly benign intracranial neoplasms that can be locally aggressive with invasion of adjacent structures. Biomarkers of aggressive behavior have been identified in the pathology literature, including the proliferative marker MIB-1. In the radiology literature, diffusion weighted imaging and low ADC values provide similar markers of aggressive behavior in brain tumors. The purpose of this study was to determine if there is a correlation between ADC and MIB-1 in pituitary macroadenomas.

Materials and methods

A retrospective review of diffusion imaging and immunohistochemical characteristics of pituitary macroadenomas was performed. The ADC ratio and specimen Ki-67 (MIB-1) indices were measured. Linear regression analysis of normalized ADC values and MIB-1 indices was used to compare these parameters.

Results

There were 17 patients with available ADC maps and MIB-1 indices. Local invasion was confirmed by imaging and intraoperative visualization in 11 patients. The mean ADC ratio for the invasive group was 0.68, with a mean MIB-1 index of 2.21 %. In the noninvasive group, the mean ADC ratio was 1.05, with a mean MIB-1 index of 0.9 %. Linear regression analysis of normalized ADC values versus MIB-1 demonstrates a negative correlation, with a linear slope significantly different from zero (p = 0.003, correlation coefficient of 0.77, and r squared = 0.59).

Conclusion

We determine a strong correlation of low ADC values and MIB-1, demonstrating the potential of diffusion imaging as a possible biomarker for atypical, proliferative adenomas, which may ultimately affect the surgical approach and postoperative management.
Literature
1.
go back to reference Asa SL, Ezzat S (1998) The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 19:798–827PubMed Asa SL, Ezzat S (1998) The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 19:798–827PubMed
2.
go back to reference Ezzat S, Asa SL, Couldwell WT et al (2004) The prevalence of pituitary adenomas: a systemic review. Cancer 101:613–619CrossRefPubMed Ezzat S, Asa SL, Couldwell WT et al (2004) The prevalence of pituitary adenomas: a systemic review. Cancer 101:613–619CrossRefPubMed
3.
go back to reference Magagna-Poveda A, Leske H, Schmid C et al (2013) Expression of somatostatin receptors, angiogenesis and proliferation markers in pituitary adenomas: an immunohistochemical study with diagnostic and therapeutic implications. Swiss Med Wkly 143:1–11 Magagna-Poveda A, Leske H, Schmid C et al (2013) Expression of somatostatin receptors, angiogenesis and proliferation markers in pituitary adenomas: an immunohistochemical study with diagnostic and therapeutic implications. Swiss Med Wkly 143:1–11
5.
go back to reference Asa SL (2008) Practical pituitary pathology: what does the pathologist need to know. Arch Pathol Lab Med 132:1231–1240PubMed Asa SL (2008) Practical pituitary pathology: what does the pathologist need to know. Arch Pathol Lab Med 132:1231–1240PubMed
6.
go back to reference Zada G, Woodmanse WW, Ramkissoon S et al (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114:336–344CrossRefPubMed Zada G, Woodmanse WW, Ramkissoon S et al (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114:336–344CrossRefPubMed
8.
go back to reference Saeger W, Ludecke DK, Buchfelder M et al (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156:203–216CrossRefPubMed Saeger W, Ludecke DK, Buchfelder M et al (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156:203–216CrossRefPubMed
9.
go back to reference Mete O, Ezzat S, Asa SL (2012) Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49:69–78CrossRef Mete O, Ezzat S, Asa SL (2012) Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49:69–78CrossRef
10.
11.
go back to reference Ginat DT, Mangla R, Yeaney G et al (2010) Correlation of diffusion and perfusion MRI with Ki-67 in high grade meningiomas. AJR 195:1391–1395CrossRefPubMed Ginat DT, Mangla R, Yeaney G et al (2010) Correlation of diffusion and perfusion MRI with Ki-67 in high grade meningiomas. AJR 195:1391–1395CrossRefPubMed
12.
go back to reference Calvar JA, Meli FJ, Romero C, Calcagno ML et al (2005) Characterization of brain tumors by MRS, DWI and Ki-67 labeling index. J Neurooncol 72:273–280CrossRefPubMed Calvar JA, Meli FJ, Romero C, Calcagno ML et al (2005) Characterization of brain tumors by MRS, DWI and Ki-67 labeling index. J Neurooncol 72:273–280CrossRefPubMed
13.
go back to reference Matsuyama J (2012) Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables. Neurol Med Chir 52:563–569CrossRef Matsuyama J (2012) Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables. Neurol Med Chir 52:563–569CrossRef
14.
go back to reference Mohamed FF, Abouhashem S (2013) Diagnostic value of apparent diffusion coefficient (ADC) in assessment of pituitary macroadenoma consistency. Egypt J Radiol Nucl Med 44:617–624CrossRef Mohamed FF, Abouhashem S (2013) Diagnostic value of apparent diffusion coefficient (ADC) in assessment of pituitary macroadenoma consistency. Egypt J Radiol Nucl Med 44:617–624CrossRef
15.
go back to reference Mahmoud OM, Tominaga A, Amatya VJ, Ohtaki M et al (2011) Role of PROPELLER diffusion weighted imaging and apparent diffusion coefficient in the evaluation of pituitary adenomas. Eur J Radiol 80:412–417CrossRefPubMed Mahmoud OM, Tominaga A, Amatya VJ, Ohtaki M et al (2011) Role of PROPELLER diffusion weighted imaging and apparent diffusion coefficient in the evaluation of pituitary adenomas. Eur J Radiol 80:412–417CrossRefPubMed
16.
go back to reference Sizuki C, Maeda M, Hori K et al (2007) Apparent diffusion coefficient of pituitary macroadenoma evaluated with line scan diffusion weighted imaging. J Neuroradiol 34:228–235CrossRef Sizuki C, Maeda M, Hori K et al (2007) Apparent diffusion coefficient of pituitary macroadenoma evaluated with line scan diffusion weighted imaging. J Neuroradiol 34:228–235CrossRef
17.
go back to reference Boxerman JL, Rogg JM, Donahue JE, Machan JT et al (2010) Preoperative MRI evaluation of pituitary macroadenoma: imaging features predictive of successful trans-sphenoidal surgery. AJR 195:720–728CrossRefPubMed Boxerman JL, Rogg JM, Donahue JE, Machan JT et al (2010) Preoperative MRI evaluation of pituitary macroadenoma: imaging features predictive of successful trans-sphenoidal surgery. AJR 195:720–728CrossRefPubMed
18.
go back to reference Pierallini A, Caramia F, Falcone C et al (2006) Pituitary macroadenomas: preoperative evaluation of consistency with diffusion weighted MR imaging- initial experience. Radiology 239:223–231CrossRefPubMed Pierallini A, Caramia F, Falcone C et al (2006) Pituitary macroadenomas: preoperative evaluation of consistency with diffusion weighted MR imaging- initial experience. Radiology 239:223–231CrossRefPubMed
19.
go back to reference Micko ASG, Wohrer A, Wolfsberger S, Knosp E (2015) Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with MRI-based classification. JNS 122:803–811 Micko ASG, Wohrer A, Wolfsberger S, Knosp E (2015) Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with MRI-based classification. JNS 122:803–811
Metadata
Title
Apparent diffusion coefficient and pituitary macroadenomas: pre-operative assessment of tumor atypia
Authors
Benita Tamrazi
Melike Pekmezci
Mariam Aboian
Tarik Tihan
Christine M. Glastonbury
Publication date
01-04-2017
Publisher
Springer US
Published in
Pituitary / Issue 2/2017
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-016-0759-5

Other articles of this Issue 2/2017

Pituitary 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.